Patients prescribed Ganfort, or Ganfort PF (bimatoprost/timolol) and Lumigan, or Lumigan PF (bimatoprost) eye drops can be enrolled in AbbVie’s free two-year program, which provides them with ongoing support through their glaucoma journey.

In addition to timely reminders to use their medication, enrolled patients receive a series of messages on their device via SMS or the MedAdvisor app, arriving at pre-determined intervals: 12 messages in year one and nine messages in year two.

As of August 2024, there are over 8,000 patients enrolled on the AbbVie adherence programs. Patients enrolled in the program have been dispensed 7.31 additional scripts versus patients not enrolled on the program. 

AbbVie has reported a 69% incremental uplift on persistence to treatment for new patients after 24 months on the adherence program.

Additionally, the company said that at 24 months, post enrollment patients demonstrated a 12% incremental uplift on adherence compared to non-program patients.

To find out more about AbbVie’s glaucoma portfolio and its patient adherence programs, please contact AbbVie on (AUS) 1800 252 224 or Eye_ Care_ANZ@abbvie.com.

PBS Information: Lumigan and Lumigan PF are listed on the PBS as eye drops for glaucoma and ocular hypertension. Ganfort 0.3/5 and Ganfort PF 0.3/5: Restricted Benefit. Reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension not adequately controlled with monotherapy.

Please review full product information before prescribing. Product information is available on request from AbbVie Pty Ltd by calling 1800 252 224 or at abbvie.com. au/ourscience/products.html.

December 2024. AU-GAN-240032.